指南与共识介入腹部DSA

多学科德尔菲共识:钇-90微球经动脉放射栓塞联合全身抗癌药物治疗肝脏恶性肿瘤的安全性

Multidisciplinary Delphi Consensus on Safety of Combining Transarterial Radioembolization with Yttrium-90 Microspheres with Systemic Anticancer Agents for the Treatment of Liver Malignancy.
指南 / 共识 · J Vasc Interv Radiol · 2024-06-15

该多学科德尔菲共识基于59篇文献形成26条关于钇-90经动脉放射栓塞(TARE)联合全身抗癌药物安全性的声明。在转移性结直肠癌中,1级证据提示奥沙利铂等放射增敏化疗需临时减量,抗血管生成靶向药应在TARE前至少停用4周;肝细胞癌中TARE联合免疫治疗可行性为4级证据,其余适应症多为5级专家意见。

要点

  • mCRC联用奥沙利铂等放射增敏化疗时需临时减量(1级证据)。
  • VEGF抑制剂和抗血管生成TKI在TARE前至少停用4周(1级证据)。
  • HCC联合免疫治疗可行性为4级证据,其他肿瘤多为5级专家意见。

核心结论

  • 在缺乏循证指南的情况下,该共识为钇-90 TARE联合特定全身抗癌药物时的潜在风险提供专家指导。

研究设计与样本

  • 改良德尔菲法,12名跨介入放射、肿瘤内科、外科肿瘤、肝病和药学专家小组,基于59篇文献对26条声明进行匿名在线调查形成共识。

诊断标准与关键数值

  • mCRC中,奥沙利铂等放射增敏化疗与钇-90 TARE联用需临时减量(1级证据)。
  • VEGF抑制剂和抗血管生成TKI在钇-90 TARE前至少停用4周(1级证据)。
  • HCC中钇-90 TARE联合免疫治疗的可行性已获4级证据证实。
  • 其他原发和继发肝脏恶性肿瘤数据有限,共识声明由专家意见驱动(5级)。

临床应用与阅片要点

  • mCRC患者考虑钇-90 TARE联合奥沙利铂等放射增敏化疗时,需注意临时减量(1级证据)。
  • 使用VEGF抑制剂或抗血管生成TKI的患者,钇-90 TARE前至少停用4周(1级证据)。
  • HCC患者联合免疫治疗已有4级证据支持可行性,其他肿瘤联合方案多基于5级专家意见。

局限性

  • 高级别证据有限(原文述High-level evidence was limited)。
  • 其他原发和继发肝脏恶性肿瘤数据更有限,共识声明由专家意见驱动(5级)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: To provide guidance, via multidisciplinary consensus statements, on the safety interactions between systemic anticancer agents (such as radiosensitizing chemotherapy, immunotherapy, targeted therapy, and peptide receptor radionuclide therapy) and transarterial radioembolization (TARE) with yttrium-90 (90Y)-labeled microspheres in the treatment of primary and metastatic liver malignancies.

MATERIALS AND METHODS: A literature search identified 59 references that informed 26 statements on the safety of 90Y TARE combined with systemic therapies. Modified Delphi method was used to develop consensus on statements through online anonymous surveys of the 12 panel members representing the fields of interventional radiology, medical oncology, surgical oncology, hepatology, and pharmacy, focusing on hepatocellular carcinoma (HCC), metastatic colorectal cancer (mCRC), neuroendocrine tumors, metastatic breast cancer, and intrahepatic cholangiocarcinoma.

RESULTS: High-level evidence was limited. Level 1 data in patients with mCRC suggest that some radiosensitizing chemotherapies (eg, oxaliplatin) require temporary dose reduction when used concomitantly with 90Y TARE, and some targeted therapies (eg, vascular endothelial growth factor inhibitors and antiangiogenic tyrosine kinase inhibitors) should be avoided for at least 4 weeks before 90Y TARE. In patients with HCC, the feasibility of 90Y TARE and immunotherapy has been demonstrated with Level 4 evidence. Data are more limited for other primary and secondary liver malignancies, and consensus statements were driven by expert opinion (Level 5).

CONCLUSIONS: Given the absence of evidence-based guidelines on the safety of 90Y TARE in combination with systemic anticancer therapy, these consensus statements provide expert guidance on the potential risks when considering specific combinations.

来源:J Vasc Interv Radiol,查看原文。版权归原作者所有。

引用

  1. Kennedy AS, Brown DB, Fakih M, et al. Multidisciplinary Delphi Consensus on Safety of Combining Transarterial Radioembolization with Yttrium-90 Microspheres with Systemic Anticancer Agents for the Treatment of Liver Malignancy. J Vasc Interv Radiol. 2024. PMID: 38885899. doi:10.1016/j.jvir.2024.06.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。